Centerline Biomedical is a technology company.
Centerline Biomedical has raised $33.0M across 1 funding round.
Centerline Biomedical has raised $33.0M in total across 1 funding round.
Centerline Biomedical has raised $33.0M in total across 1 funding round.
Centerline Biomedical's investors include Refinery Ventures.
Centerline Biomedical is a Cleveland-based technology company specializing in advanced medical navigation systems for endovascular procedures. Its flagship product, the Intra-Operative Positioning System (IOPS®), is an FDA-cleared, 3D visualization and real-time navigation platform that enhances surgical precision while significantly reducing harmful radiation exposure for patients and clinicians. The system integrates electromagnetic tracking with 3D vascular mapping to provide interactive guidance during minimally invasive vascular surgeries, improving outcomes and procedural efficiency. Centerline serves vascular surgeons and interventionalists, addressing the critical need for safer, more accurate image guidance in complex endovascular interventions. The company has demonstrated growth momentum with over 200 procedures performed using IOPS and recent FDA clearances expanding its clinical applications, with plans for broader market deployment by late 2024 and beyond[1][2][3][5].
Founded in 2014 as a spinoff from the Cleveland Clinic's Lerner Research Institute, Centerline Biomedical was established by a multidisciplinary team including scientists, clinicians, and engineers dedicated to transforming vascular navigation. The idea emerged from the need to overcome limitations of traditional 2D X-ray fluoroscopy, which exposes patients and staff to radiation and provides low-quality imaging. Early traction came from the development and FDA clearance of the IOPS platform, which combined electromagnetic navigation with 3D imaging to create a GPS-like system for vascular procedures. This innovation was recognized with industry awards and adoption at leading vascular centers, marking pivotal moments in the company’s evolution[1][3][4].
Centerline Biomedical is riding the trend toward minimally invasive, image-guided interventions that prioritize patient and provider safety. The timing is critical as endovascular procedures grow in complexity and volume, increasing radiation risks. Market forces favor technologies that improve visualization while reducing radiation exposure and procedural costs. Centerline’s IOPS platform addresses these demands by offering a safer, more precise alternative to traditional fluoroscopy, influencing the broader ecosystem by setting new standards for surgical navigation and fostering innovation in vascular care and medical device technology[4][6].
Looking ahead, Centerline Biomedical is positioned to expand its market reach with recent FDA clearances enabling broader clinical applications. The company is expected to continue enhancing its platform’s capabilities, including predictive modeling and healthcare analytics, further integrating into diverse vascular and structural heart procedures. Trends such as increasing demand for minimally invasive surgeries, radiation safety awareness, and digital health integration will shape its trajectory. Centerline’s influence is likely to grow as it drives a paradigm shift toward safer, more effective endovascular navigation, benefiting patients, clinicians, and the healthcare system at large[3][5][6].
Centerline Biomedical has raised $33.0M across 1 funding round. Most recently, it raised $33.0M Series B in June 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2022 | $33.0M Series B | Refinery Ventures |